The fastest evidence-based depression treatment currently available is the SAINT protocol, a precision-targeted form of TMS that compresses 50 sessions into five days and achieves a 78.6% remission rate. Ketamine infusions can reduce symptoms within hours, though relief typically fades within days to weeks without maintenance. For treatment-resistant cases, combining TMS with CBT produces a 56% remission rate. Each approach carries distinct tradeoffs in speed, durability, and relapse risk worth exploring further.
The fastest way to treat depression will vary depending on the individual and the severity of their symptoms. In some cases, a combination of medication and therapy may be the most effective way to treat depression quickly. Medications known as antidepressants can help to regulate the chemicals in the brain that are thought to be involved in depression and can often provide relief from symptoms within a few weeks. Therapy, such as cognitive-behavioral therapy (CBT), can help to identify and change negative thought patterns and behaviors that may be contributing to the person’s depression.
Five-Day Depression Treatment With a 78% Remission Rate
When standard antidepressants fail, and they do for roughly one-third of patients, the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol offers a compelling alternative. Among the fastest clinical depression interventions available, SAINT delivers 10 theta-burst stimulation sessions daily over five consecutive days, 50 total sessions producing rapid depression relief. In a double-blind randomized controlled trial, 78.6% of treatment-resistant participants achieved remission, with 85.7% showing significant response.
Unlike rapid-acting pharmacologic options in supervised settings, SAINT uses precision-targeted brain stimulation rather than medication. SAINT achieves this precision through fMRI and neuronavigation to individually map and target the dorsolateral prefrontal cortex for each patient. This individualized approach is critical because small deviations in targeting can significantly impact treatment outcomes. When paired with crisis-focused therapy or CBT, remission rates climb further. As one of today’s most validated intensive programs and accelerated treatment approaches, SAINT compresses six weeks of standard TMS into five days, with 60% maintaining remission at one month. A 2024 pilot trial further reinforced these findings, demonstrating the protocol’s effectiveness, safety, and lasting antidepressant effects.
Ketamine for Depression: Fast Relief, Fading Results
Though SAINT rewires neural circuits through magnetic stimulation, ketamine takes a fundamentally different pharmacologic route, and delivers results even faster. You can experience significant symptom reduction within one hour of your first infusion, with dark thoughts often dissipating first.
The numbers are compelling: 60, 70% of patients show marked improvement, and 52% achieve remission after just three infusions over 11 days. Average MADRS scores drop from 28 to 11 within 24 hours of the third dose, particularly striking for treatment-resistant cases where traditional antidepressants have failed.
Here’s the tradeoff: relief lasts only days to weeks without maintenance. You’ll likely need booster infusions to sustain benefits. Side effects, primarily transient dissociation, resolve within an hour, offering better tolerability than ECT.
TMS and CBT as a Faster Path to Depression Remission
Pairing transcranial magnetic stimulation with cognitive behavioral therapy ramps up remission rates beyond what either intervention achieves alone. In treatment-resistant patients, this combination yields 56% remission and 66% response, roughly five times the remission likelihood compared to sham controls. You don’t face higher dropout rates with combined treatment, making it a practical option.
Accelerated TMS protocols compress weeks of daily sessions into days. The SAINT protocol, which uses intensive individualized stimulation over the left dorsolateral prefrontal cortex, achieves 80% remission within days. Standard rTMS still produces measurable symptom relief within one week, with 54% clinical response. You’ll typically complete 20, 30 minute outpatient sessions without anesthesia, experiencing only mild headaches or fatigue. Benefits can persist up to a year, though ongoing care remains essential.
Same-Day Depression Strategies That Support Recovery
Several interventions now deliver measurable depression relief within hours, not weeks. Ketamine infusions produce symptom reduction within hours of a single session, with 50, 70% of patients responding positively. Esketamine (Spravato) demonstrates antidepressant effects within 24 hours of the first dose, administered under clinical supervision during 2-hour monitored sessions.
These rapid-acting treatments don’t replace sustained care, they bridge the gap. After six ketamine infusions over 1, 2 weeks, response rates exceed 50%, with 20, 25% achieving remission. Esketamine reaches approximately 52.5% remission by week four when paired with an oral antidepressant.
You should view same-day strategies as catalysts, not cures. They stabilize acute symptoms quickly, giving longer-term treatments like TMS, psychotherapy, or medication optimization time to consolidate lasting recovery.
How to Choose the Fastest Depression Treatment for You?
When you’re weighing rapid-acting options against sustained approaches, treatment selection depends on three clinical variables: symptom severity, prior treatment history, and your tolerance for relapse risk.
If you’ve failed two antidepressants, pursuing a third yields less than 2% success. SAINT-iTBS offers 60% remission within weeks, but carries a 50% six-month relapse rate. CBT delivers comparable response rates (58% at 16 weeks) with markedly lower relapse (26-31% at one year).
Your strongest clinical strategy combines modalities. Network meta-analyses across 9,301 patients confirm combined psychotherapy and pharmacotherapy outperforms either alone. If speed is critical, initiate TMS or medication for acute stabilization, then layer CBT for durable remission. This sequential approach maximizes rapid symptom reduction while protecting against the high discontinuation-relapse rates associated with monotherapy.
The National Depression Hotline is available 24/7/365 to help you or a loved one talk about depression and the next steps for depression treatment. Call for free at (866) 629-4564.
Frequently Asked Questions
Does Insurance Cover SAINT-TMS or Esketamine Nasal Spray Treatments?
Most insurers cover esketamine (Spravato) for treatment-resistant depression once you’ve failed two or more antidepressants and meet prior authorization requirements. You’ll typically pay copays and deductibles under your medical benefit. SAINT-TMS isn’t widely covered yet, you’ll likely pay $6,000, $15,000 out of pocket, but coverage is expanding, with CMS reimbursement codes launching July 2025. You should contact your insurer directly to verify your plan’s specific coverage details.
Can Children or Adolescents Safely Receive Accelerated TMS Protocols?
Yes, adolescents can safely receive accelerated TMS protocols. Research shows theta burst stimulation is well-tolerated in teens, with mild side effects like temporary headache and scalp discomfort occurring at rates similar to adults. The FDA has cleared rTMS for treatment-resistant depression in adolescents aged 15 and older. If your child’s younger, it’s used off-label with extra supervision. You’ll want a provider experienced in pediatric neuromodulation protocols.
How Does Depression Treatment Speed Differ for Bipolar Versus Unipolar Depression?
Your bipolar depression typically responds faster to certain interventions, you’ll likely need fewer ECT sessions than someone with unipolar depression, and you’ll often show more rapid clinical improvement overall. Ketamine can lift symptoms within hours regardless of subtype. However, you face higher treatment-resistance rates, and unopposed antidepressants risk triggering mania, so clinicians must carefully select mood stabilizers or anticonvulsants alongside rapid-acting therapies to guarantee safe, sustained response.
Are Rapid Depression Treatments Safe During Pregnancy or Breastfeeding?
Most rapid treatments carry specific risks you should weigh carefully. ECT is considered safe during pregnancy for severe depression, while benzodiazepines show low harm evidence during breastfeeding for short-term use. However, you can’t safely use brexanolone during pregnancy or breastfeeding, and zuranolone lacks sufficient safety data for either. Sertraline remains a well-studied option with reassuring breastfeeding profiles. You’ll want to consult your provider and resources like LactMed for individualized guidance.
What Happens if the Fastest Depression Treatments Stop Working Over Time?
If rapid treatments like ketamine or accelerated TMS lose effectiveness, you’re not out of options. You can explore maintenance TMS sessions, switch or augment antidepressants, or add evidence-based psychotherapy. Research shows TMS durability improves with biweekly maintenance, and Spravato’s remission rates hold better with ongoing optimization. Since antidepressants alone achieve only ~26% remission after multiple trials, your clinician may recommend combining pharmacological and non-pharmacological strategies to sustain your response.
